Table 1.

Baseline Characteristics and Selected Chemotherapy of the PRO-Evaluable Population (abdominal/GI symptoms) and the Intent-to-Treat Population

Characteristic	PRO-Evaluable Population				Intent-to-Treat Population
	Chemotherapy Alone (n = 162)		Bevacizumab Plus Chemotherapy (n = 155)		Chemotherapy Alone (n = 182)		Bevacizumab Plus Chemotherapy (n = 179)
	No. of Patients	%	No. of Patients	%	No. of Patients	%	No. of Patients	%
Age, years
Median	61		62		61		62
Range	32-84		25-80		25-84		25-80
Origin of cancer: ovary	140	86	143	92	157	86	167	93
Serous/adenocarcinoma at diagnosis	138	85	135	87	152	84	156	87
Histologic grade at diagnosis
1	8	5	8	5	9	5	10	6
2	40	25	49	32	48	26	53	30
3	95	59	77	50	105	58	94	53
Two prior chemotherapy regimens	72	44	65	42	78	43	72	40
Platinum-free interval < 3 months*†	38	23	42	27	46	25	50	28
ECOG PS
0	89	55	95	61	99	54	107	60
1	59	36	47	30	69	38	58	32
2	11	7	11	7	11	6	12	7
Missing	3	2	2	1	3	2	2	1
Measurable disease	158	98	152	98	144	79	143	80
Ascites	49	30	50	32	54	30	59	33
Selected chemotherapy
Weekly paclitaxel	46	28	48	31	55	30	60	34
Pegylated liposomal doxorubicin	59	36	57	37	64	35	62	35
Topotecan	57	35	50	32	63	35	57	32

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; PRO, patient-reported outcome.

^*Stratification factor.

^†From last platinum to subsequent disease progression.